<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823184</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/27</org_study_id>
    <nct_id>NCT02823184</nct_id>
  </id_info>
  <brief_title>Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms</brief_title>
  <acronym>PhiNESS</acronym>
  <official_title>Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the endoplasmic reticulum stress markers as predictive
      for response to hydroxyurea in polycythemia vera (PV) and essential thrombocythemia (ET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recent discovery of calreticulin mutations in myeloproliferative neoplasms point to the
      unexpected role of the endoplasmic reticulum biology in the pathophysiology in these
      diseases. Otherwise, the association of endoplasmic reticulum stress with solid cancers, in
      particular in resistance to chemotherapy, is well documented, contrary to hematological
      malignancies. The study aims to evaluate endoplasmic reticulum stress markers as predictors
      for the response to hydroxyurea in polycythemia vera and essential thrombocythemia patients.
      The main objective is to correlate endoplasmic reticulum stress (defined as splicing of XBP1
      above 30%) to the rate of complete response after 6 months according to the 2009 ELN
      criteria. This is an observational retrospective study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To correlate endoplasmic reticulum stress (defined as splicing of XBP1 above 30%) to the rate of complete response after 6 months according to the 2009 ELN criteria</measure>
    <time_frame>After 6 months of treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Essential Thrombocythemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RNA sample of total leukocytes before start of treatment</intervention_name>
    <description>RNA sample of total leukocytes before start of treatment</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Polycythemia Vera or Essential Thrombocythemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with
             a follow up period of at least 6 months following treatment start.

          -  Diagnosis criteria of PV :

               -  WHO criteria of PV with :

                    -  Acquired JAK2V617F mutation &gt; 5%

                    -  Absence of evident cause of secondary polycythemia

          -  Diagnosis criteria of ET :

               -  Platelet count &gt; 450 G/L

               -  Absence of PV or Chronic Myeloid Leukemia

               -  Bone marrow biopsy preferred but not necessary in absence of reactional causes
                  (CRP and ferritin levels normal) and/or presence of acquired JAK2V617F, CALR exon
                  9 or MPL exon 10

          -  Availability of RNA sample of total leukocytes before start of treatment.

        Exclusion Criteria:

        In absence of clonality marker, presence of secondary cause of :

          -  Thrombocytosis :

               -  Inflammatory syndrom (CRP or SV increased)

               -  Iron deficiency (decreased ferritin level or increased soluble transferrin
                  receptor level)

          -  Polycythemia :

               -  Increased or normal level of EPO in context of :

                    -  Hypoxia, respiratory insufficiency

                    -  Sleep apnea syndrome

                    -  Hyperaffin hemoglobin

          -  Absence of treatment by hydroxyurea

          -  Treatment by anagrelide, P32, pipobroman, interferon without subsequent hydroxyurea
             treatment.

          -  Concommitant treatment by other cancer chemotherapy (in a context of solid cancer for
             example).

          -  Diagnostic during transformation to acute leukemia

          -  Treatment by hydroxyurea during less than 6 months

          -  Bad observance of the cytotoxic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier MANSIER, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier MANSIER, Doctor</last_name>
    <phone>05 56 79 56 79</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.mansier@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ch de La Cöte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric BAUDUER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MANSIER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crlcc Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel ETIENNE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Libourne</name>
      <address>
        <city>Libourne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier ADIKO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie GACHARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Nimes</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serge CARILLO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric DELABESSE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloproliferative neoplasms</keyword>
  <keyword>Endoplasmic reticulum stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

